trending Market Intelligence /marketintelligence/en/news-insights/trending/VC64cwywPNoGp9U2v89lrQ2 content esgSubNav
In This List

Pfizer hikes price for 91 drugs in the US

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Pfizer hikes price for 91 drugs in the US

Pfizer Inc. increased the U.S. prices of its 91 drugs by 5% to 13% on June 1, the Financial Times reported.

In 2017, the company has reportedly raised the price on several drugs by an average of 20%, while the price increase is even higher in some cases.

Pfizer said it has priced its products responsibly and it believes innovative medicines to be among the most valuable and cost effective segments of healthcare spend, Financial Times reported, citing a company spokesperson.

The spokesperson also stated that the company provides comprehensive and extensive access programs for patients who cannot afford their products or lack good health insurance.

Pfizer did not join other big pharmaceutical companies such as Allergan PLC, AbbVie Inc. and Sanofi in their pledge to cap annual price increases to less than 10% per year.